Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response
Maddalena Marconato, Irène A. Abela, Anthony Hauser, Magdalena Schwarzmüller, Rheliana Katzensteiner, Dominique L. Braun, Selina Epp, Annette Audigé, Jacqueline Weber, Peter Rusert, Eméry Schindler, Chloé Pasin, Emily West, Jürg Böni, Verena Kufner, Michael Huber, Maryam Zaheri, Stefan Schmutz, Beat M. Frey, Roger D. Kouyos, Huldrych F. Günthard, Markus G. Manz, Alexandra Trkola
Abstract
Neutralizing antibodies are considered a key correlate of protection by current SARS-CoV-2 vaccines. The manner in which human infections respond to therapeutic SARS-CoV-2 antibodies, including convalescent plasma therapy, remains to be fully elucidated.
Topics & Concepts
MedicineAntibodyViremiaImmunologyHazard ratioConvalescent plasmaViral loadNeutralizing antibodyNeutralizationInternal medicineVirologyConfidence intervalCoronavirus disease 2019 (COVID-19)DiseaseVirusInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCOVID-19 Impact on Reproduction